Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | +0.00% |
About
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA, overvalu